Can the vascular endothelial growth factor (VEGF) inhibitor bevacizumab (Avastin) treat hereditary hemorrhagic telangiectasia (HHT) epistaxis? Background: HHT is an autosomal dominant disorder involving abnormal blood vessel development. An estimated […]
